SPY381.72-1.91 -0.50%
DIA318.25+3.01 0.95%
IXIC12,609.16-310.99 -2.41%

BRIEF-Cstone Pharmaceuticals Says Sugemalimab Granted Breakthrough Therapy Designation

· 02/07/2021 20:25
BRIEF-Cstone Pharmaceuticals Says Sugemalimab Granted Breakthrough Therapy Designation

- CStone Pharmaceuticals 2616.HK:

  • ANTI-PD-L1 ANTIBODY SUGEMALIMAB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY CHINA NMPA CENTER FOR DRUG EVALUATION

Source text for Eikon: ID:nHKS5w4M4T

Further company coverage: 2616.HK


((reuters.briefs@thomsonreuters.com))